CAPTIVA TRIAL - StrokeNet

 


LOGO__CAPTIVA-Blue (002)
Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)

 


STUDY OVERVIEW:

CAPTIVA is a two-stage prospective, randomized, double-blinded, clinical trial conducted in subjects age 30 and older with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery: carotid artery, middle cerebral artery (M1 or M2), vertebral artery (V4), basilar artery, posterior cerebral artery (P1), or anterior cerebral artery (A1). CAPTIVA will enroll up to 1,683 subjects at over 100 US sites.

Subjects in the first stage, were randomized 1:1:1 to one year of treatment with:

  • ticagrelor + aspirin, or
  • low dose rivaroxaban + aspirin, or
  • clopidogrel + aspirin

At the completion of the first stage of the study in January 2026, the Data and Safety Monitoring Board recommended, and the National Institute of Neurological Disorders and Stroke approved, termination of the low dose rivaroxaban arm.

Subjects in the second stage, will be randomized 1:1 to one year of treatment with:

  • ticagrelor + aspirin, or
  • clopidogrel + aspirin

All subjects will receive intensive risk factor management and lifestyle coaching similar to that in the SAMMPRIS and CREST-2 trials.

All subjects will be evaluated at 1 month, 4 months, 8 months, and 12 months.

The main intent of CAPTIVA is to establish that at least one of the two novel therapies, low dose rivaroxaban or ticagrelor, is more effective than the current standard. CAPTIVA is not designed or powered to answer which of the two therapies is more effective – that would require a much larger sample size. Nevertheless, CAPTIVA will provide important safety and efficacy data on both therapies.


Meet the CAPTIVA Investigators

  • Brian Hoh, MD, MBA, FACS, FAHA, FAANS | Co-Principal Investigator

  • Marc I. Chimowitz, MBChB | Co-Principal Investigator



IN THE NEWS